AWAlan William Walker

Alan William Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alan William Walker has a total of 799 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Environmental enteric dysfunction influences linear growth of children through insulin-like growth factor-1: findings from the Indonesian Action Against Stunting Hub birth cohort

    by Min Kyaw Htet, Mifa Nurfadilah, Tiffany C. Angelin, Benjamin Momo Kadia, Isobel L. Gabain, Anouschka S. Ramsteijn, Hilary Davies-Kershaw, Beatriz Calvo-Urbano, Joanne P. Webster, Alan W. Walker, et al.

    Poor gut health, characterized by persistent immune activation and increased intestinal permeability, is considered a significant underlying cause of impaired child growth. This study aimed to investigate effects of environmental enteric dysfunction (EED) and systemic inflammation on plasma insulin-like growth factor (IGF)-1 and linear growth among Indonesian infants. In this longitudinal cohort study (Action Against Stunting Hub), faecal and plasma samples were collected at six months of age, and anthropometry assessment was conducted at six and twelve months of age. EED markers included faecal myeloperoxidase, alpha-1 antitrypsin and plasma intestinal fatty acid binding protein (IFABP). Systemic inflammation markers included C-reactive protein, alpha-1 acid glycoprotein and cluster of differentiation-14 (CD14). IGF-1 was measured as a growth biomarker. Correlation and multivariable regression analyses assessed association with length-for-age z-score (LAZ). Structural equation modelling explored potential pathways. Elevated EED markers were common among the infants (>80%). Maternal height, birth weight and IGF-1 were significant determinants of LAZ at 12 months. Pathway analysis showed IGF-1 was negatively associated with CD14, whereas CD14 was positively associated with IFABP. EED influences linear growth indirectly through systemic inflammation and altered growth signalling. Studies to further address gut integrity and systemic inflammation to improve linear growth are recommended. This article is part of the theme issue ‘Biological, biomedical and environmental drivers of stunting’.


  • Open Access

    Exploring the diet–microbiome–growth axis among under-2-year-old children: a case–control study in East Lombok, Indonesia

    by Min Kyaw Htet, Mifa Nurfadilah, Anouschka S. Ramsteijn, Tiffany C. Angelin, Amanda S. Ameline, Benjamin Momo Kadia, Isobel L. Gabain, Hilary Davies-Kershaw, Beatriz Calvo-Urbano, Joanne P. Webster, et al.

    Previous studies have compared the microbiota profiles of stunted and non-stunted children. However, how these profiles interact with dietary patterns is not completely understood. To assess differences in microbial diversity, composition and bacteria taxa between stunted and non-stunted children and how the consumption of food groups influence the gut microbiota of stunted children, this matched case–control study was conducted among 150 pairs of stunted and non-stunted children of between 18–23 months old in East Lombok, Indonesia. Anthropometry and dietary data were collected by trained enumerators. Microbiome data were generated by sequencing the V4 hypervariable region of the 16S rRNA gene. No between-group differences in alpha and beta diversity were observed. Exploratory analysis identified that Agathobacter, Coprococcus, Dorea, Hominimerdicola, Lawsonibacter and Ruminococcoides were more proportionally abundant among non-stunted children and Peptostreptococcus among stunted children. However, there was no association between food group consumption and abundance of these taxa. Breastfeeding significantly shaped the microbiota profiles. Future research on the association between microbiota profiles and complementary feeding should incorporate approaches such as diet modelling to capture the combined contributions of food groups and dietary components, alongside longitudinal study designs. This article is part of the theme issue ‘Biological, biomedical and environmental drivers of stunting’.

  • Open Access

    Assessment of inter-individual variation in metabolism of flavonoids from bilberry and grape seed extracts using an in vitro digestion and faecal fermentation model

    by T. Grohmann, P. A. Kroon, M. Philo, G. Horgan, X. Zhang, U. Balaseviciute, A. W. Walker, W. R. Russell, N. Hoggard, B. de Roos

    The gut microbiota plays an essential role in the conversion of anthocyanins and (epi-)catechins into smaller phenolic acids, which are then absorbed into the blood stream. The phenolic composition of a commercial bilberry extract and grape seed extract was assessed, as well as a formulation extract containing a combination of both extracts. The extracts were subjected to an in vitro salivary, gastric and intestinal digestion environment, based on the INFOGEST Model. The solid fraction end-product of the combined extract from the in vitro digestion was further fermented with faecal samples from six healthy donors, for 72 hours, to assess phenolic acid metabolism, short-chain fatty acid formation and changes in microbial composition. During the in vitro digestion, flavonoid content in all three extract samples (bilberry, grape seed and the formulation extracts) decreased significantly. In the process of anthocyanin and flavonoid digestion, smaller phenolic acid compounds such as benzoic acid, cinnamic acid and mandelic acid increased in bilberry, grape seed and formulation extract samples. All faecal donors harboured unique microbiota compositions, however all faecal microbiota were able to fully convert catechin/epicatechin, the most prominent flavonoids in the formulation extract sample, into smaller phenolic metabolites (phenylacetic, phenylpropionic and benzoic acids) within 24 hours. Using 16S rRNA gene amplicon sequencing, Anaerobutyricum and Enterocloster spp. were correlated with catechin/epicatechin metabolism in the fermentation procedure, however, in single bacterial strain fermentation experiments with the formulation extract or catechin standard, these bacteria were not capable of metabolising flavonoids. Highlights: Faecal microbiota converted (epi-)catechin to phenolic metabolites within 24 h. (Epi-)catechin correlated negatively with Anaerobutyricum and Enterocloster spp. Faecal bacterial cultures did not show (epi-)catechin metabolism capacity.

  • Top Cited Papers
    Open Access

    Microbiota and kidney disease: the road ahead

    by Patricia P. Bloom, Wendy S. Garrett, Kristina L. Penniston, Mari-Karoliina H. Winkler, Stanley L. Hazen, Jose Agudelo, Mangesh Suryavanshi, Ahmed Babiker, Dylan Dodd, Michael A. Fischbach, et al.

    More than 850 million individuals worldwide, accounting for 10–15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota — a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.


  • Top Cited Papers
    Open Access

    Guidelines for preventing and reporting contamination in low-biomass microbiome studies

    by Noah Fierer, Pok Man Leung, Rachael Lappan, Raphael Eisenhofer, Francesco Ricci, Sophie I. Holland, Nicholas Dragone, Linda L. Blackall, Xiyang Dong, Cristina Dorador, et al.

    Numerous important environments harbour low levels of microbial biomass, including certain human tissues, the atmosphere, plant seeds, treated drinking water, hyper-arid soils and the deep subsurface, with some environments lacking resident microbes altogether. These low microbial biomass environments pose unique challenges for standard DNA-based sequencing approaches, as the inevitability of contamination from external sources becomes a critical concern when working near the limits of detection. Likewise, lower-biomass samples can be disproportionately impacted by cross-contamination and practices suitable for handling higher-biomass samples may produce misleading results when applied to lower microbial biomass samples. This Consensus Statement outlines strategies to reduce contamination and cross-contamination, focusing on marker gene and metagenomic analyses. We also provide minimal standards for reporting contamination information and removal workflows. Considerations must be made at every study stage, from sample collection and handling through data analysis and reporting to reduce and identify contaminants. We urge researchers to adopt these recommendations when designing, implementing and reporting microbiome studies, especially those conducted in low-biomass systems.


  • Open Access

    Assessing the safety of microbiome perturbations

    by Aline Metris, Alan W. Walker, Alicia Showering, Andrea Doolan, Andrew J. McBain, Antonis Ampatzoglou, Barry Murphy, Catherine O'NEill, Colette Shortt, Elizabeth M. Darby, et al.

    Everyday actions such as eating, tooth brushing or applying cosmetics inherently modulate our microbiome. Advances in sequencing technologies now facilitate detailed microbial profiling, driving intentional microbiome-targeted product development. Inspired by an academic-industry workshop held in January 2024, this review explores the oral, skin and gut microbiomes, focussing on the potential long-term implications of perturbations. Key challenges in microbiome safety assessment include confounding factors (ecological variability, host influences and external conditions like geography and diet) and biases from experimental measurements and bioinformatics analyses. The taxonomic composition of the microbiome has been associated with both health and disease, and perturbations like regular disruption of the dental biofilm are essential for preventing caries and inflammatory gum disease. However, further research is required to understand the potential long-term impacts of microbiome disturbances, particularly in vulnerable populations including infants. We propose that emerging technologies, such as omics technologies to characterize microbiome functions rather than taxa, leveraging artificial intelligence to interpret clinical study data and in vitro models to characterize and measure host–microbiome interaction endpoints, could all enhance the risk assessments. The workshop emphasized the importance of detailed documentation, transparency and openness in computational models to reduce uncertainties. Harmonisation of methods could help bridge regulatory gaps and streamline safety assessments but should remain flexible enough to allow innovation and technological advancements. Continued scientific collaboration and public engagement are critical for long-term microbiome monitoring, which is essential to advancing safety assessments of microbiome perturbations.


  • Open Access

    Improving gut health and growth in early life: a protocol for an individually randomised, two-arm, open-label, controlled trial of a synbiotic in infants in Kaffrine District, Senegal

    by Benjamin Momo Kadia, Marietou Khouma, Doudou Sow, Babacar Faye, Anouschka S Ramsteijn, Beatriz Calvo-Urbano, Modou L Jobarteh, Elaine Ferguson, Paul Haggarty, Joanne P Webster, et al.

    Introduction: Infants exposed to enteropathogens through poor sanitation and hygiene can develop a subclinical disorder of the gut called environmental enteric dysfunction (EED), characterised by abnormal intestinal histology and permeability. EED can contribute to stunting through reduced digestion and absorption of nutrients, increased susceptibility to infections, increased systemic inflammation and inhibition of growth hormones. EED can be apparent by age 12 weeks, highlighting the need for early intervention. Modulating the early life gut microbiota using synbiotics may improve resistance against colonisation of the gut by enteropathogens, reduce EED and improve linear growth.Methods and analysis: An individually randomised, two-arm, open-label, controlled trial will be conducted in Kaffrine District, Senegal. Infants will be recruited at birth and randomised to either receive a synbiotic containing twoBifidobacteriumstrains and oneLactobacillusstrain, or no intervention, during the first 6 months of life. The impact of the intervention will be evaluated primarily by comparing length-for-age z-score at 12 months of age in infants in the intervention and control arms of the trial. Secondary outcome variables include biomarkers of intestinal inflammation, intestinal integrity and permeability, gut microbiota profiles, presence of enteropathogens, systemic inflammation, growth hormones, epigenetic status and episodes of illness during follow-up to age 24 months.Discussion: This trial will contribute to the evidence base on the use of a synbiotic to improve linear growth by preventing or ameliorating EED in a low-resource setting.Trial registration number: PACTR202102689928613.


  • Open Access

    Assessment of the role of gut health in childhood stunting in a multisite, longitudinal study in India, Indonesia and Senegal: a UKRI GCRF Action Against Stunting Hub protocol

    by Benjamin Momo Kadia, Anouschka S Ramsteijn, Teena Dasi, Umi Fahmida, Bharati Kulkarni, Babacar Faye, Min Kyaw Htet, Doudou Sow, Rajender Rao Kalashikam, Ritu Sharma, et al.

    Introduction Childhood stunting has a complex aetiology, with poor gut health being an important contributor. This study will assess inter-relationships between maternal and infant gut health indices and infant linear growth. Inter-relationships between gut health indices, systemic inflammation and growth hormones in early childhood will also be assessed. Methods and analysis A longitudinal observational study of cohorts of 600 newborns and their mothers in India, Indonesia and Senegal will be conducted. Women will be recruited during pregnancy and their children followed up to age 24 months. Stool, urine and blood samples will be collected from the women and children for assessments of helminthic and protozoal parasites, bacterial pathogens, faecal microbiota taxa, biomarkers of environmental enteric dysfunction, systemic inflammation and growth hormones. Child anthropometric measurements will be collected at birth and at ages 3, 6, 9, 12, 18 and 24 months. The gut health indices will be integrated with cohort data from other Action Against Stunting Hub (AASH) workstreams for interdisciplinary analyses of childhood stunting and the development of a new typology of stunting. Discussion This study will advance scientific understanding of the role of gut health in childhood stunting and will contribute to a broader knowledge of the complex aetiology of this condition as part of the interdisciplinary AASH research to reduce the global burden of childhood stunting. Ethics and dissemination This study has been approved by the relevant Ethics Committees in Senegal, India, and Indonesia and LSHTM. The results will be submitted for publication in peer-reviewed journals.


  • Open Access

    Anthropometric, biochemical, dietary, morbidity and well-being assessments in women and children in Indonesia, India and Senegal: a UKRI GCRF Action Against Stunting Hub protocol paper

    by Hilary Davies-Kershaw, Umi Fahmida, Min Kyaw Htet, Bharati Kulkarni, Babacar Faye, Dwi Yanti, Dewi Shinta, Nur L Zahra, Tiffany C Angelin, Radhika Madhari, et al.

    Introduction Child stunting has a complex aetiology, especially in the first 1000 days of life. Nutrition interventions alone have not produced expected impacts in reducing/preventing child stunting, indicating the importance of understanding the complex interplay between environmental, physiological and psychological factors influencing child nutritional status. This study will investigate maternal and child nutrition, health and well-being status and associated factors through the assessment of: (1) anthropometry, (2) biomarkers of nutrition and health status, (3) dietary intakes, (4) fetal growth and development, (5) infant morbidity, (6) infant and young child feeding (IYCF) and (7) perinatal maternal stress, depression and social support. Methods This study will be conducted in a prospective pregnancy cohort in India, Indonesia and Senegal. Pregnant women will be recruited in the second (Indonesia, Senegal) and third (India) trimester of pregnancy, and the mother and infant dyads followed until the infant is 24 months of age. During pregnancy, anthropometric measures will be taken, venous blood samples will be collected for biochemical assessment of nutrition and health status, dietary intakes will be assessed using a 4-pass-24-hour dietary recall method (MP24HR), fetal ultrasound for assessment of fetal growth. After birth, anthropometry measurements will be taken, venous blood samples will be collected, MP24HR will be conducted, infant morbidity and IYCF practices will be assessed and a sample of breastmilk will be collected for nutrient composition analyses. Perinatal maternal stress, depression, social support and hair cortisol levels (stress) will be measured. The results from this study will be integrated in an interdisciplinary analysis to examine factors influencing infant growth and inform global efforts in reducing child stunting. Ethics and dissemination Ethical approval was granted by the Ethics Committee of the London School of Hygiene and Tropical Medicine (17915/RR/17513); National Institute of Nutrition (ICMR)-Ministry of Health and Family Welfare, Government of India (CR/04/I/2021); Health Research Ethics Committee, University of Indonesia and Cipto Mangunkusumo Hospital (KET-887/UN2.F1/ETIK/PPM.00.02/2019); and the Comité National d'Ethique pour la Recherche en Santé, Senegal (Protocole SEN19/78); the Royal Veterinary College (URN SR2020-0197) and the International Livestock Research Institute Institutional Research Ethics Committee (ILRI-IREC2020-33). Results will be published in peer-reviewed journals and disseminated to policy-makers and participating communities.


  • Human microbiome myths and misconceptions

    by Alan W. Walker, Lesley Hoyles

    Over the past two decades, interest in human microbiome research has increased exponentially. Regrettably, this increased activity has brought with it a degree of hype and misinformation, which can undermine progress and public confidence in the research. Here we highlight selected human microbiome myths and misconceptions that lack a solid evidence base. By presenting these examples, we hope to draw increased attention to the implications of inaccurate dogma becoming embedded in the literature, and the importance of acknowledging nuance when describing the complex human microbiome.